Navigation Links
MD Anderson Cancer Center joins Actinium Pharmaceuticals' (API) Multicenter Actimab-A Trial
Date:9/12/2012

NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).  The trial is designed to establish safety and efficacy of API's drug Actimab-A in AML patients over the age of 60.  Actimab-A treatment consists of the isotope Actinium 225 attached to the anti-CD33 monoclonal antibody lintuzumab (HuM195). 

"This is an important milestone in the development of our drug candidate," said Jack Talley, CEO of Actinium Pharmaceuticals.  "MD Anderson is a leading cancer treatment institution and treats more patients with acute myeloid leukemia than any other center in the world.  We view their joining our trial as a key vote of confidence for our innovative, world class technology."

MD Anderson is the third center to sign a clinical trial agreement with Actinium Pharmaceuticals, following Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY and Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington.

Phase I/II multi-center Actimab study will build on the previous phase I/II Bismab-A study with a less potent bismuth-213 (Bi-213) isotope and an earlier Actimab-A phase 1 study (where only a single dose of Actimab was administered).  The Phase II portion of the earlier Bismab-A study demonstrated the efficacy of API's alpha particle platform by producing a number of complete responses in difficult-to-treat relapsed, secondary and poor cytogenetics AML patients with no standard of care options available. The goal of the current study is to confirm efficacy and safety of Actimab-A using the same antibody targeting mechanism with the actinium isotope, produced by an improved method of manufacture, and to study the effect of mu
'/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical Site Services Chris Trizna Contributing Author in Diana Anderson-Fosters Newest Release Global Issues in Patient Recruitment and Retention
2. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
3. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
4. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
5. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
6. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
7. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
8. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. New research points to benefits of innovative cobasĀ® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
11. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Research and Markets  has announced the addition of ... Chromatograph Market by Type , Technology, Spectroscopy, Gas chromatography, ... to 2013 - 2020" report to their offering. ... analytical instrument that provides chemical composition data on process ... which companies carry out their production and improve the ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
(Date:9/29/2014)... 2014  The 12th Cold Chain GDP & ... September 29 at the John B. Hynes Convention Center. ... for a weeklong conference attracting industry executives ... is designed to cover the industry,s most pressing topics, ... all temperature range products, GDP compliance requirements and supply ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 212th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2
... KYOTO, Japan and MARCY L,ETOILE, France , ... today that they have entered into a partnership to ... microbiology laboratories. bioMerieux will work with Shimadzu and their ... spectrometry technology for optimized integration into the microbiology laboratory ...
... , May 21 Micromet, Inc. (Nasdaq: MITI ... next-generation antibodies for the treatment of cancer, today announced that updates ... at two upcoming medical conferences. , ... Blinatumomab (MT103), the Company,s lead product candidate, will ...
... , BRISBANE, Calif. , May 21 InterMune, Inc. (Nasdaq: ... Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at ... May 26 at 3 p.m. EDT . , ... To access a live audio webcast of the presentation, investors ...
Cached Biology Technology:Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 2Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 3Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 4Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences 2Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences 3InterMune to Present at 2010 Citi Health Care Conference 2
(Date:9/29/2014)... inhibitor dabrafenib has significant anti-tumour activity in patients ... cancer whose disease has progressed after chemotherapy, according ... 2014 Congress in Madrid, Spain. , "Reports ... generated considerable interest because these mutations may be ... agents," says lead author Dr David Planchard, pulmonary ...
(Date:9/29/2014)... in French . ... of days an expectant mother was deprived of electricity ... of her child, a new study finds., Scientists from ... have detected a distinctive ,signature, in the DNA of ... ice storm. Five months after the event, researchers recruited ...
(Date:9/29/2014)... a previously unknown mechanism by which estrogen prepares ... of estrogen-positive breast cancers, resist cancer drugs. The ... breast cancer therapy and will help doctors predict ... The University of Illinois team reports its findings ... pre-activates the unfolded-protein response (UPR), a pathway that ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... world over, are hungry for more meat, milk and ... has prompted explosive growth in livestock production and massive ... new textbook, Animal Manure Recycling: Treatment and Management, draws ... to put environmental problems to work and ensure the ...
... Department of Energy is making good on the second phase of ... study led by Dr. Joshua Yuan, Texas A&M AgriLife Research plant ... Yuan, who was granted $1.8 million for Phase I ... potential fuel source., The scientist said his research is moving ahead ...
... a new model for a genetic eye disease, and shows ... monkeys can yield valuable information about the human brain. ... of the Society for Neuroscience and the world,s largest source ... models have long been central in how we understand the ...
Cached Biology News:New textbook tackles the sustainable recycling of manure 2Plant fuel project moves to second phase under US Energy Department grant 2Understanding ourselves by studying the animal kingdom 2
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Biology Products: